Neura Market
CB Insights - The AI in drug R&D market map - May 2025 logo

CB Insights - The AI in drug R&D market map - May 2025

Free

Mapping 225 AI-driven drug R&D companies across 27 markets

FreeFree tier
Type
Open Source
Company
CB Insights
Visit Website GitHub (38 stars)

About CB Insights - The AI in drug R&D market map - May 2025

CB Insights' AI in Drug R&D Market Map (May 2025) provides a comprehensive analysis of 225 AI-driven drug research and development companies across 27 markets. The report includes key findings on commercial maturity, funding trends, and high-growth areas such as patient recruitment platforms and clinical trial management systems. It highlights that clinical development AI tools are more commercially mature than preclinical applications, with AI funding in drug R&D rebounding to $3.8 billion in 2024. The map is designed to help pharmaceutical companies, investors, and researchers understand the competitive landscape and identify opportunities for leveraging AI to accelerate drug discovery and reduce costs.

Key Features

Market map of 225 AI-driven drug R&D companies across 27 markets
Analysis of commercial maturity stages for clinical vs. preclinical AI tools
Funding trends and rebounding investment data (2024: $3.8B in equity funding)
Identification of high-growth areas: patient recruitment platforms and clinical trial management systems
Key takeaways on AI adoption in pharmaceutical R&D, cost pressures, and time savings (up to 30% reduction in clinical trial times)
Proprietary metrics: Mosaic scores, Commercial Maturity assessments, and exit probability

Pros & Cons

Pros
  • Comprehensive coverage of 225 companies across 27 markets
  • Data-driven insights backed by CB Insights' proprietary metrics (Mosaic, Commercial Maturity)
  • Highlights both emerging preclinical opportunities and mature clinical tools
  • Useful for identifying high-growth sub-sectors like patient recruitment platforms
  • Includes historical and current funding data with 2025 momentum analysis
Cons
  • Market map is not intended to be exhaustive; categories are not mutually exclusive
  • Snapshot nature (May 2025) may become outdated as the field evolves rapidly
  • Preclinical section noted as most nascent with limited late-stage companies
  • Focus on private companies may miss some public or non-covered entities

Best For

Pharmaceutical R&D strategy planning and portfolio optimizationInvestor analysis of AI drug discovery landscape and funding trendsCompetitive intelligence for drug development AI companiesAcademic research on AI applications in preclinical and clinical developmentBenchmarking commercial maturity of AI drug R&D firms

FAQ

What is the scope of this market map?
The map covers 225 AI-driven drug R&D companies across 27 markets, focusing on both preclinical and clinical development applications. It is not intended to be exhaustive, and categories are not mutually exclusive.
What key trends does the report highlight?
It highlights that clinical development AI tools are more commercially mature than preclinical ones, AI funding in drug R&D rebounded in 2024 to $3.8B, and patient recruitment platforms and clinical trial management systems show the strongest momentum based on Mosaic scores and deal growth.
How can I access the full report?
The report is available on the CB Insights website. A free trial of CB Insights is offered, and the report appears to be freely accessible as part of their research.